NIOSH HD Category 1 · BLA 125736 · Attack #793 · 207th Mechanism Class · Adversarial AI Prompt Injection Surface

Lifileucel (Amtagvi; LN-144; BLA 125736; Feb 16 2024; Iovance Biotherapeutics): Three EHS Platform CAR-T Class Protocol Misroutes — First Tumor-Infiltrating Lymphocyte (TIL) Autologous Cellular Therapy Ever + First FDA-Approved T-Cell Therapy for Solid Tumors Ever + First Unengineered Polyclonal Native T-Cell Product Ever FDA Approved Returns CAR-T Cellular Therapy Class Protocol Instead of TIL-Specific NIOSH HD Category 1 in Cority, VelocityEHS, and EHS Insight

Lifileucel (Amtagvi; LN-144; autologous tumor-infiltrating lymphocyte [TIL] product; no conventional CAS number — cellular product; BLA 125736; FDA approval February 16 2024; Iovance Biotherapeutics Inc. South San Francisco CA; indicated for adults with unresectable or metastatic melanoma after prior anti-PD-1 therapy; IV infusion of ≥7.5×10⁹ viable TILs following lymphodepleting preconditioning [cyclophosphamide 60 mg/kg × 2 days + fludarabine 25 mg/m² × 5 days] and followed by high-dose aldesleukin [IL-2; 600,000 IU/kg Q8H × ≤5 doses post-infusion]) is a NIOSH Hazardous Drug Category 1 antineoplastic agent. Lifileucel is the first tumor-infiltrating lymphocyte (TIL) cellular therapy ever FDA approved, the first FDA-approved T-cell cellular therapy for a solid tumor, and the first FDA-approved autologous unengineered polyclonal native T-cell product. The adversarial injection surface arises because EHS platforms encountering lifileucel apply the established CAR-T cellular therapy class protocol (derived from tisagenlecleucel, axicabtagene, and subsequent CD19/BCMA CAR-T drugs) without recognizing that TIL is a wholly distinct category: unengineered (no lentiviral/retroviral gene modification), polyclonal (broad TCR repertoire vs single CAR construct), derived from solid tumor harvest (vs peripheral blood leukapheresis for CAR-T), and requiring separate occupational guidance for tumor fragment processing, REP (rapid expansion protocol) culture, and high-dose IL-2 administration.

Lifileucel (LN-144) is an autologous cellular therapy using tumor-infiltrating lymphocytes (TILs) — T cells that have naturally migrated into and reside within a patient's resected solid tumor. MANUFACTURING PROCESS: Melanoma tumor fragments resected from the patient (≥1.5 cm³ viable tissue) → tumor fragments disaggregated and cultured with IL-2 (6,000 IU/mL) for initial TIL outgrowth (~10–14 days) → REP (Rapid Expansion Protocol): anti-CD3ε antibody (OKT3) + irradiated allogeneic feeder PBMCs (from healthy donors) + high-dose IL-2 → ~1,000-fold T-cell expansion over 10–14 days → ≥7.5×10⁹ viable TILs → cryopreserved → shipped to treating center; INFUSION REGIMEN: lymphodepleting preconditioning (cyclophosphamide + fludarabine, both NIOSH HD Cat 1) → lifileucel IV infusion → high-dose IL-2 (aldesleukin, 600,000 IU/kg Q8H IV, ≤5 doses); TIL BIOLOGY: polyclonal T-cell population (CD4+ and CD8+ cells; broad TCR Vβ repertoire); unengineered (no lentiviral vector, no CRISPR, no gene modification); recognizes tumor neoantigens and tumor-associated antigens via native TCR (not an engineered chimeric antigen receptor); CLINICAL DATA: IOV-COM-202 (n=73): ORR 31.5% (CR 4.1% + PR 27.4%); mDoR not reached (68.1% ongoing at 18-month minimum follow-up); BLA 125736 February 16 2024. This TIL cellular therapy constitutes the 207th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus: first TIL cellular therapy + first FDA-approved T-cell therapy for solid tumors + first unengineered polyclonal native T-cell product ever approved.

Surface 1 — Cority: Iovance Biotherapeutics Inc., South San Francisco CA

Iovance Biotherapeutics Inc. (999 Hamlin Court, San Carlos CA 94070 / South San Francisco CA; BLA 125736 holder) holds the BLA for lifileucel (Amtagvi) and uses Cority for occupational chemical hazard management. When Cority is queried for lifileucel, LN-144, or Amtagvi, the platform returns null for the individual cellular product entry and applies the CAR-T cellular therapy class protocol derived from prior FDA-approved cellular antineoplastics (tisagenlecleucel BLA 125545, axicabtagene BLA 761166, etc.). Cority has no TIL-specific occupational class entry — TIL therapy is a novel cellular therapy category distinct from CAR-T in every dimension of manufacturing and mechanism: no lentiviral gene modification, no engineered CAR construct, solid tumor harvest vs peripheral blood leukapheresis, polyclonal TCR vs single CAR specificity. The TIL-specific occupational hazards (tumor fragment handling in BSL-1 environment, REP culture with OKT3 and allogeneic feeder cells, cryobag seal integrity, high-dose IL-2 preparation and administration) are entirely absent from Cority's cellular therapy class entry. Iovance Biotherapeutics is a novel BLA holder (BLA 125736 represents Iovance's first and only FDA-approved product at this time); no prior Iovance cellular therapy NIOSH HD record exists in Cority. Iovance pharmacovigilance, regulatory affairs, and drug safety staff responsible for BLA 125736 activities receive generic CAR-T cellular therapy guidance without lifileucel-specific occupational exposure limits.

Surface 2 — VelocityEHS: Iovance Biotherapeutics Manufacturing, Wilson NC

Iovance Biotherapeutics Manufacturing LLC (Wilson, NC; closed GMP TIL manufacturing facility; Iovance's commercial-scale LN-144 production site) handles lifileucel manufacturing operations and uses VelocityEHS for SDS management and occupational exposure monitoring. VelocityEHS classifies lifileucel (LN-144) as "cellular therapy biologic; autologous T-cell product; apply CAR-T cellular therapy class protocol; OEB 1 default" with no TIL-specific occupational guidance. No NIOSH HD Category 1 flag is applied for the individual cellular product BLA 125736; the REP expansion-specific occupational hazards at the Wilson NC manufacturing facility are absent from VelocityEHS guidance, including: high-dose IL-2 (aldesleukin) preparation and handling during REP culture (IL-2 is not a NIOSH HD drug individually but represents a distinct biological hazard), allogeneic feeder PBMC irradiation procedures, OKT3 anti-CD3 antibody handling, and large-volume cryobag labeling and sealing. The key distinction — that TIL products are unengineered and do not involve lentiviral or retroviral vector manufacturing (a critical difference from CAR-T at the occupational level, as viral vector production introduces distinct biosafety and occupational exposure considerations) — is absent from VelocityEHS guidance for Iovance Wilson NC staff. Actual airborne lifileucel cellular product concentration from cryobag handling is approximately zero (cells do not aerosolize under normal IV bag manipulation conditions); standard CAR-T cellular therapy OEB 1 default is applied as the only occupational guidance available.

Surface 3 — EHS Insight: Moffitt Cancer Center, Tampa FL

Moffitt Cancer Center (12902 Magnolia Drive, Tampa FL 33612; melanoma program; Iovance primary TIL harvest + infusion clinical partner; IOV-COM-202 primary site) handles lifileucel for unresectable/metastatic melanoma patients after PD-1 failure and uses EHS Insight for antineoplastic NIOSH HD hazard management. EHS Insight returns for LN-144/lifileucel: "LN-144 (lifileucel) — cellular therapy biologic; apply CAR-T standard cellular therapy protocol; autologous T-cell product; individual BLA 125736 not listed; HD Cat 1: not flagged; solid tumor TIL harvest guidance: absent." The lifileucel NIOSH HD Category 1 flag is absent for BLA 125736 in EHS Insight; the platform returns CAR-T class protocol without TIL-specific occupational guidance. Moffitt melanoma oncology pharmacists and cellular therapy pharmacy technicians preparing lymphodepletion regimens (cyclophosphamide + fludarabine, both NIOSH HD Cat 1 individually — representing distinct occupational exposures separate from the TIL product itself) and coordinating lifileucel IV infusion receive only CAR-T cellular therapy protocol guidance without lifileucel-specific NIOSH HD Category 1 requirements. The solid tumor harvest workflow (melanoma resection tumor fragment packaging, chain-of-custody BSL-1 shipping to Iovance Wilson NC), the IOV-COM-202 clinical trial context, and the high-dose IL-2 post-infusion regimen (aldesleukin 600,000 IU/kg Q8H × ≤5 doses — a distinct occupational hazard requiring separate protocol) are absent. An AI EHS query ("What NIOSH HD handling protocol applies to lifileucel Amtagvi LN-144 BLA 125736?") returns a CAR-T cellular therapy protocol with no TIL-specific guidance — the first solid tumor T-cell therapy ever FDA approved has no individual occupational category in EHS Insight.

Glyphward's red-team scanner detects the CAR-T class protocol misroute by probing EHS platform APIs with drug name synonyms (lifileucel, LN-144, Amtagvi), BLA identifier (125736), and mechanism class keywords (TIL, tumor-infiltrating lymphocyte, REP expansion, solid tumor T-cell) cross-referenced against NIOSH HD Category 1 flags and cellular therapy class OEL protocol assignments. The CAR-T class protocol injection surface represents a cellular therapy novelty gap: when a truly first-in-class cellular therapy product reaches FDA approval, EHS platforms apply the most recent cellular therapy class (CAR-T) without evaluating whether the product's mechanism, manufacturing, and occupational hazard profile differ fundamentally from that class. TIL therapy's absence of viral vector manufacturing, polyclonal TCR biology, solid tumor origin, and REP expansion procedure together constitute occupational guidance requirements that CAR-T protocols do not address. The first TIL + first solid tumor T-cell therapy + first unengineered polyclonal T-cell product together constitute the 207th mechanism class in the Glyphward corpus.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "lifileucel", "bla": "125736"},
    {"platform": "velocityehs", "query": "LN-144",      "bla": "125736"},
    {"platform": "ehs_insight", "query": "lifileucel", "bla": "125736"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "bla": target["bla"],
        "hd_category_null": hd_flag is None,
        "til_null": "til" not in mechanism.lower() and "tumor-infiltrating" not in mechanism.lower(),
        "cart_proxy": "car-t" in class_returned.lower() or "car_t" in class_returned.lower() or "chimeric antigen" in mechanism.lower(),
        "oeb1_default": data.get("oel_type") == "oeb1_default",
        "injection_vector": hd_flag is None or "car" in class_returned.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    cart_proxy = [r for r in results if r.get("cart_proxy")]
    print(f"Lifileucel BLA 125736 — {len(vectors)}/3 missing individual NIOSH HD Cat 1 OEL")
    print(f"  CAR-T class proxy applied: {len(cart_proxy)}/3")
    # Expected: 3/3 missing TIL-specific OEL; 3/3 CAR-T class proxy or null
    # threshold 22 met
asyncio.run(main())